Tumor necrosis factor-α induces increased lung vascular permeability: a role for GSK3α/β

Eur J Pharmacol. 2011 Apr 25;657(1-3):159-66. doi: 10.1016/j.ejphar.2011.01.060. Epub 2011 Feb 12.

Abstract

We tested the hypothesis that glycogen synthase kinase 3α/β (GSK3α/β) modulates tumor necrosis factor-a (TNF) induced increased lung vascular permeability. Rats were treated with TNF (i.v., ~100ng/ml) or vehicle 0.5h, 4.0h and 24.0h prior to lung isolation. Rats were co-treated with the GSK3α/β inhibitors SB216763 (0.6mg/kg) or TDZD-8 (1.0mg/kg). After TNF, the isolated lung was assessed for hemodynamics, wet-dry/dry weight (W-D/D) and extravascular albumin. Extravascular albumin significantly increased at TNF-24h compared to Control. In the GSK3α/β-inhibited+TNF groups, extravascular albumin was similar to the Control and respective SB216763 and TDZD-8 groups. In separate studies, to assess GSK3α/β-activity, lung lysate was assessed for phospho-GSK3α/β-Ser(21/9), total GSK3α/β, un-phospho-β-catenin-Ser(33/37) and total β-catenin. In the TNF-4.0h group, there was no change in GSK3α/phospho-GSK3α-Ser(21) but there was an increase in GSK3β/GSK3β-Ser(9) compared to Control, indicating GSK3β activation at TNF-4.0h. GSK3β activation was verified because there was a decrease in un-phospho-β-catenin-Ser(33/37)/β-catenin in the TNF-4.0 group, a specific outcome for GSK3β activation. In the SB216763+TNF group, un-phospho-β-catenin-Ser(33/37) was similar to Control, indicating prevention of TNF-induced GSK3β activation. In the TNF-24h group, there were increases in the biomarkers of inflammation phospho-eNOS-Ser (1117) and oxidized protein, which did not occur in the SB216763+TNF-24h and TDZD-8+TNF-24h groups. In the SB216763+TNF-24h and TDZD-8+TNF-24h groups, un-phospho-β-catenin-Ser(33/37) was greater than in the Control, indicating continued inhibition of GSK3β. The data indicates that pharmacologic inhibition of GSK3β inhibits TNF induced increased endothelial permeability associated with lung inflammation.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Capillary Permeability / drug effects*
  • Enzyme Activation / drug effects
  • Glycogen Synthase Kinase 3 / antagonists & inhibitors
  • Glycogen Synthase Kinase 3 / metabolism*
  • Glycogen Synthase Kinase 3 beta
  • Humans
  • Indoles / pharmacology
  • Lung / drug effects*
  • Lung / enzymology
  • Lung / metabolism*
  • Male
  • Maleimides / pharmacology
  • Nitric Oxide Synthase Type III / metabolism
  • Oxidation-Reduction
  • Phosphoproteins / chemistry
  • Phosphoproteins / metabolism
  • Phosphorylation / drug effects
  • Protein Kinase Inhibitors / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Serine / metabolism
  • Thiadiazoles / pharmacology
  • Time Factors
  • Tumor Necrosis Factor-alpha / pharmacology*
  • Tyrosine / metabolism
  • beta Catenin / chemistry
  • beta Catenin / metabolism

Substances

  • 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
  • Biomarkers
  • Indoles
  • Maleimides
  • Phosphoproteins
  • Protein Kinase Inhibitors
  • SB 216763
  • Thiadiazoles
  • Tumor Necrosis Factor-alpha
  • beta Catenin
  • Tyrosine
  • Serine
  • Nitric Oxide Synthase Type III
  • GSK3B protein, human
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, rat
  • Glycogen Synthase Kinase 3
  • glycogen synthase kinase 3 alpha